Russian cloud service for decoding the genome entered the US market

    According to RBC, a promising cloud service from Russia is strengthening its position in the American markets, allowing doctors to diagnose a patient based on decoding of genomic data. “We are another tool for helping a doctor, like a scalpel, a pack of cotton wool or a microscope. We help diagnose when it’s difficult, ”says Andrei Afanasyev, founder of iBinom startup. The service works on the principle of searching for a needle in a haystack.

    The human genome consists of 3 billion pairs of nucleides - indivisible elements in the structure of DNA, which are a set of genetic "letters". iBinom uses special software to find the exact “letter” in the chain in which the mutation occurred that caused the hereditary disease. This interpretation of the DNA structure is called genome sequencing.

    Andrei Afanasyev claims that iBinom allows you to determine which substitution in the protein led to a mutation and whether it is pathogenic.

    IBinom was founded in 2013. In addition to Afanasyev, the founders of the company are Valery Ilyinsky and Ignat Kolesnichenko. The idea of ​​the project was formed at the junction of biotechnology and Big Data.

    For processing big data, ready-made solutions were used, as well as a self-written integration code.



    “They took partially ready-made blocks - open source software with university licenses, partially developed the bundle themselves. All this works in the cloud on Amazon Web Services, there is EC2 (Elastic Compute Cloud) and S3 (Simple Storage Service) storage system. We built a pipeline, a sequence of running programs, ”says Afanasyev.

    “It's just as if you were predicting the weather, looking not at the sky, but at 47 different sites on the Internet. Different programs give different predictions, and then there is an algorithm that weighs these predictions and ultimately gives some kind of integrated assessment, ”explains Mikhail Gelfand, professor at the Department of Bioengineering and Bioinformatics, Moscow State University.

    Having prepared a business plan, the founders turned to the business incubator of Moscow State University. In addition, the startup received an investment of $ 22,000 from the venture capital funds LETA Capital and AltaIR Capital, as well as from the management company of the business incubator Universe Ventures.

    iBinom is the only graduate of the MSU business incubator, in which the LETA Capital fund has re-invested. In October 2013, iBinom received another $ 100,000 from him. Further search for investors dragged on and lasted almost the whole of 2014. In December alone, the company finally received $ 300,000 from two Russian business angels.

    One of the advantages of iBinom is a higher speed of work with large amounts of data compared to competitors.

    The second advantage is the ability to upload to the cloud service an infinite number of analyzes that will be processed in a short time.

    The third advantage of iBinom is the “pathogenicity rate” function, which more accurately than others determines mutations not previously described.

    According to BCC Research, in 2012 the share of genome sequencing services in the world market was $ 3.5 billion. By 2018, it is forecasted to grow to $ 11.7 billion.

    Andrei Afanasyev believes that iBinom will be able to become part of any leading company in the future in the field of cloud computing, or part of a large company that provides sequencing services.

    Also popular now: